Hintergrund: Die konventionelle Trabekulektomie (TET) stellt trotz einem eher ungünstigen Komplikationsprofil weiterhin den Goldstandard der operativen Glaukomtherapie dar, da sie eine effektivere langfristige Drucksenkung als neuere Operationsverfahren aufweist. Fragestellung: Vergleich der Erfolgsquote und des Risikoprofils der TET mit einer durch Schaffen einer zweiten Filtrationsebene sowie Vermeiden einer peripheren Iridektomie modifizierten Trabekulektomie („Filtrierende Trabekulotomie“ (FTO)). Material und Methode: Retrospektiv durchgeführter intraindividueller Vergleich über 36 Monate an 20 Patienten mit Offenwinkelglaukom nach TET an einem Auge und FTO am anderen Auge an der Augenklinik der Universität Würzburg. Primärer Endpunkt war das Erreichen des absoluten/Teilerfolgs (IOD ≤18 mmHg und ≥ 20 % Druckreduktion ohne/mit Medikation). Als sekundäre Endpunkte wurden das Auftreten von Komplikationen sowie der Verlauf von Augeninnendruck, Visus und lokaler Pharmakotherapie analysiert. Ergebnisse: Beide Operationsverfahren führten zu einer signifikanten Reduktion des Augeninnendrucks zu jedem postoperativen Zeitpunkt. Nach 36 Monaten zeigte sich ein absoluter Erfolg bei 50 % der Augen in der TET-Gruppe und 20 % der FTO-Gruppe sowie ein Teilerfolg bei 71,4 % gegenüber 33,3 %. Zu Komplikationen kam es mit Ausnahme des häufigeren Auftretens eines Hyphämas in der FTO-Gruppe in vergleichbarem Ausmaß in beiden Gruppen. Der Visus und postoperative Medikamentenscore unterschieden sich nicht signifikant voneinander. Schlussfolgerung: Die TET war der FTO in Hinblick auf Erfolg und Komplikationsrisiko überlegen. Die möglichen Vorteile der Operation durch die genannten Modifikationen konnten nicht bestätigt werden. / Background: Despite its numerous short- and long-term complications Trabeculectomy (TET) remains the gold standard of surgical management of glaucoma. It offers more effective IOP control than minimal invasive glaucoma surgery. Objectives: Comparison of the outcome of the TET and a modified trabeculectomy with a second outflow-resistance level of the aqueous humor and without iridectomy (“Filtering Trabeculotomy” (FTO)). Methods: Intraindividual comparison of 20 patients with open-angle glaucoma after TET on the first eye and FTO of the other eye in a retrospective design over a follow-up period of 36 month. Primary outcome measure was the rate of complete and qualified success (IOP ≤18 mmHg and ≥ 20 % reduction without/with medication). Secondary outcome measures were the development of IOP, visual acuity, anti-glaucoma medication and complications. Results: Both surgical procedures reduced the IOP significantly. After 36 month of follow-up 50 % of the patients in the TET-group and 20 % in the FTO-group had a complete success. For qualified success there were lower rates with 71,4 % and 33,3 %, respectively. Complications were comparable in both groups with the exception of hyphema, which was seen more frequently in the FTO-group. Visual acuity and anti-glaucoma medication did not differ significantly. Conclusions: TET was superior to the FTO regarding success rates and complications. Potential benefits of the modifications of the surgical procedure could not be proved.

Purpose To evaluate the effectiveness and safety of Selective Laser Trabeculoplasty (SLT) with the SLT mode of the VISULAS ® green laser in patients with primary open-angle glaucoma (POAG). Methods This prospective, interventional multicenter clinical investigation included patients with POAG who either needed a treatment escalation because the individual intraocular pressure (IOP) target was not met or treatment initiation and had an IOP ≥ 17 mmHg at baseline in the study eye. The study was conducted in five research centers across Germany. Approximately 100 laser applications were delivered to 360° of the trabecular meshwork. Glaucoma medications were not modified during the 3-month follow-up to allow evaluation of the sole effect of VISULAS ® green with SLT. Efficacy outcomes were postoperatively absolute and relative IOP changes at 1 and 3 months. Safety outcomes analyzed the rate of intra- and postoperative adverse events. Results Thirty-four eyes of 34 POAG patients were included. The overall mean number of preoperative glaucoma medications was 2.2 ± 1.4 in 29 treated eyes, 5 eyes were treatment naïve. Mean baseline IOP (mmHg) was 21.0 ± 2.69 and was reduced by − 3.53 ± 3.34 [95% CI − 4.61; − 2.45] and − 3.59 ± 3.41 [95% CI − 4.64; − 2.53] at the 1- and 3-month follow-up, respectively (p < 0.0001), with 48.5% of cases achieving a ≥ 20% IOP reduction at 3 months [95% CI = 30.8%; 66.5%]. The mean relative IOP reduction was − 16.4% and − 16.3% at 1 and 3 months, respectively (p < 0.0001). Potentially device- or procedure-related adverse events were mild to moderate and included 3 postoperative IOP-spikes and 6 reports regarding eye pain and discomfort. All were resolved without sequelae. Conclusions SLT performed with the VISULAS ® green laser achieved clinically significant additional IOP reductions in medically treated as well as in treatment naïve eyes with POAG and there were no relevant safety issues. The results are comparable to other reported SLT studies.